Fermented oyster extract FGO,
does it really help with Promotion of height growth in children?
research showsKorean placebo-controlled trials using FGO 500 mg/day for 24 weeks report greater height gain and annualized height velocity. All trials, however, concern the same proprietary ingredient, cluster around company development networks, and did not measure the most important long-term outcome in growing children: final adult height. Only the short-term growth signal is rated C.
ads claimClaims can expand into 'increases final height,' 'stimulates growth plates,' or 'overcomes genetic limits.' The measured outcomes were 24-week height change, annualized velocity, and selected hormone or bone-turnover markers, not adult height.
Useful facts when choosing a product
- In South Korea, FGO is commercialized as an individually recognized functional ingredient for child height growth; recognition confirms that a dossier exists, not independent replication or final-height proof.
- All pivotal public trials used FGO 500 mg/day for 24 weeks.
- Results cannot be transferred to ordinary oyster foods or extracts with different fermentation strains, GABA content, or standardization.
- Children with oyster or shellfish allergy should avoid it, and mild rash occurred in some trial participants. Long-term pediatric and post-pubertal safety remain insufficiently established.
What the research actually shows
The Jeong 2021 RCT randomized 100 children aged 6 to 11 years at or below the 25th height percentile to FGO 500 mg/day or placebo, and 93 completed 24 weeks; height gain was significantly greater with FGO. The Kim 2026 RCT randomized 80 children aged 6 to 9, then reported a per-protocol analysis of 66 after exclusions and withdrawals: height gain was 3.40 versus 2.48 cm and annualized velocity 7.32 versus 5.40 cm/year. The Jeon 2026 trial also reported 24-week height gains of 3.22 versus 2.38 cm among 80 children. None followed final adult height.
Why this is classified as C (52)
Repeated placebo-controlled RCTs support a short-term height-gain signal and place the evidence near the upper end of C. Positive evidence remains concentrated in the same proprietary ingredient and company development network, with only 24-week surrogates and no final adult-height or independent long-term replication, so the score is 52.
Counterpoint. A between-group difference of roughly 0.8 to 0.9 cm over 24 weeks is not a signal to dismiss. Whether higher velocity produces greater final height is a separate question that remains unanswered.
Rejudgment record. New verdict — Positive 24-week RCTs of one proprietary ingredient, limited by manufacturer concentration, short-term growth surrogates, and no final-height data
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Twenty-four-week height gain and height velocity | C | Korean RCTs of the same proprietary ingredient at 500 mg/day are positive but concentrated in a company-linked, short-term evidence base |
| Increase in final adult height | ? | No human efficacy study followed participants to growth completion and compared final adult height |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Jeong A et al. 2021 | Randomized double-blind placebo-controlled trial | 93 | Ministry of Oceans and Fisheries project; two ingredient-company authors | Twenty-four-week height gain, height SDS, and height velocity | Height gain was significantly greater with 500 mg/day than with placebo. | Key |
| Kim J et al. 2026 | Randomized double-blind placebo-controlled trial | 66 | Ministry of Oceans and Fisheries grant; most authors affiliated with LG Household & Health Care | Twenty-four-week height gain, velocity, IGF-1, and bone age | Height gain was 3.40 versus 2.48 cm and velocity 7.32 versus 5.40 cm/year. | Replication with company concentration |
| Jeon YJ et al. 2026 | Randomized double-blind placebo-controlled trial | 80 | Includes Marine Bioprocess authors; detailed funding confirmation limited | Twenty-four-week height gain, velocity, and bone age | Height gain was reported as 3.22 versus 2.38 cm, without final-height follow-up. | Supportive proprietary evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Fermented oyster extract FGO x height growth in children — Evidence Grade C·52. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/fermented-oyster-extract-fgo-child-height/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.